Can I stop using crizotinib after surgery?

Whether crizotinib can be stopped after surgery is a question that requires comprehensive consideration of many factors.

After receiving crizotinib treatment, if the disease progression slows down or reaches a stable state, patients may have the idea of discontinuing the drug. However, discontinuation must be preceded by thorough discussion and careful evaluation. This includes regular imaging and clinical evaluation to ensure the disease is not progressing further.

The patient's physical condition and ancillary laboratory test results are also important factors to consider before discontinuing medication. If the patient is in good physical condition and laboratory test results are normal, this may provide some basis for discontinuation of the drug.

For patients with ALK-positive or ROS1-positive non-small cell lung cancer, it is also necessary to consider whether the patient's genetic test results remain stable before stopping treatment.

There is a risk of tumor recurrence or progression after stopping crizotinib. This is because crizotinib controls tumor development by inhibiting the growth of cancer cells, and once the drug is stopped, the cancer cells may start to multiply again.

Long-term use of crizotinib may lead to mutations in ALK or ROS-1 proteins, making cancer cells resistant to the drug. After discontinuation, the efficacy of re-administration of crizotinib may be greatly reduced due to the development of drug resistance.

Stopping the drug may lead to a decrease in the patient's quality of life and symptoms such as difficulty breathing, hemoptysis, and fatigue, which may seriously affect the patient's daily life and work ability. In addition, discontinuation of medication may have a negative impact on the patient's mental health and increase the patient's stress and anxiety.